期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 69, 期 -, 页码 97-99出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2009.117143
关键词
-
类别
资金
- Arthritis Research Campaign
- Kennedy Institute of Rheumatology Trustees
- Trillium Therapeutics Inc
- Nuon Therapeutics Inc
Anti-tumour necrosis factor (anti-TNF) therapy of patients with rheumatoid arthritis dates back to 1992, when the first proof-of-principle trials were performed in London by Maini and Feldmann. Considerable studies of the mechanism of action were performed, and insights into the way in which anti-TNF therapy delivers its benefit were obtained. In this brief review, certain aspects of knowledge acquired and the many gaps will be reviewed. Focus will be on the TNF-dependent cytokine cascade and what it means, and potential new approaches to treatment. Finally, an entertaining challenge: might many or even all unmet clinical needs be dealt with through cytokine analysis?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据